The fair value of the Company's available-for-sale investments at and were million and million, respectively. The million increase in the Company’s available-for-sale investments was driven by a million increase in the fair value of the Company’s investment in ChemoCentryx, Inc (CCXI) from million at to million at This increase was partially offset by the maturity of million in corporate bond securities held by Advanced Cell Diagnostics (ACD) and million in certificate of deposits held in China. The cost basis of the Company's investment in CCXI at and was million.

 

 

Inventories consist of (in thousands): 

		March 31,				June 30,
		2018				2017
Raw materials		$	29,414			$	22,074
Finished goods			59,172				38,077
Inventories, net		$	88,586			$	60,151

 

Property and equipment consist of (in thousands):

		March 31,				June 30,
		2018				2017
Land		$	7,064			$	6,270
Buildings and improvements			172,305				158,495
Machinery and equipment			106,058				98,596
Property and equipment, cost			285,427				263,361
Accumulated depreciation and amortization			(142,648	)			(128,237	)
Property and equipment, net		$	142,779			$	135,124

 

Intangible assets consist of (in thousands):

		March 31,				June 30,
		2018				2017
Developed technology		$	292,825			$	276,959
Trade names			88,961				87,092
Customer relationships			214,107				204,243
Non-compete agreements			3,286				3,264
Patents			1,242				633
Intangible assets			600,421				572,191
Accumulated amortization			(156,627	)			(120,149	)
Intangible assets, net		$	443,794			$	452,042

 

Changes to the carrying amount of net intangible assets for the months ended consist of (in thousands):

 

Beginning balance		$	452,042
Acquisitions			23,292
Other additions			796
Amortization expense			(34,611	)
Currency translation			2,275
Ending balance		$	443,794

 

The estimated future amortization expense for intangible assets as of is as follows (in thousands):

 

2018		$	11,953
2019			47,125
2020			46,422
2021			46,035
2022			44,213
Thereafter			248,046
Total		$	443,794

 

Changes to the carrying amount of goodwill for the months ended consist of (in thousands):

 

		Biotechnology				Protein Platforms				Diagnostics				Total
Beginning balance		$	254,930			$	220,826			$	103,270			$	579,026
Acquisitions (Note 3)			27,686				-				113				27,799
Currency translation			3,416				454				(28	)			3,842
Ending balance		$	286,032			$	221,280			$	103,355			$	610,667

 

We evaluate the carrying value of goodwill in the quarter of each year and between annual evaluations if events occur or circumstances change that would indicate a possible impairment. The Company performed a quantitative assessment for all of its reporting units during the quarter of fiscal year The quantitative assessment indicated that all of the reporting units had substantial headroom as of

 

triggering events were identified during the quarter ended There has been impairment of goodwill since the adoption of Financial Accounting Standards Board (“FASB”) ASC guidance for goodwill and other intangibles on

 

Other Assets consist of (in thousands):

		March 31,				June 30,
		2018				2017
Investments		$	24,181			$	40,385
Other			2,883				3,617
Other assets		$	27,064			$	44,002

 

As of the Company had million of other assets compared to million as of The Company holds a ownership interest in Astute Medical, Inc. (Astute) and accounts for this investment under the cost method. During the quarter the Company learned that Asute intended to accept an offer to sell the company to a party. As a result of this triggering event, the Company completed an impairment assessment and determined that a portion of its investment in Astute was other-than-temporarily impaired and adjusted the carrying value of this investment by million during the quarter to other income (expense) in the accompanying condensed consolidated Statement of Earnings and Comprehensive Income. The Company’s net investment in Astute was million at